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Human digestive carboxypeptidases CPA1, CPA2, and
CPB1 are secreted by the pancreas as inactive proenzymes
containing a 94–96-amino acid-long propeptide. Activation
of procarboxypeptidases is initiated by proteolytic cleavage
at the C-terminal end of the propeptide by trypsin. Here, we
demonstrate that subsequent cleavage of the propeptide by
chymotrypsin C (CTRC) induces a nearly 10-fold increase in
the activity of trypsin-activated CPA1 and CPA2, whereas
CPB1 activity is unaffected. Other human pancreatic pro-
teases such as chymotrypsin B1, chymotrypsin B2, chymo-
trypsin-like enzyme-1, elastase 2A, elastase 3A, or elastase
3B are inactive or markedly less effective at promoting pro-
carboxypeptidase activation. On the basis of these observa-
tions, we propose that CTRC is a physiological co-activator
of proCPA1 and proCPA2. Furthermore, the results confirm
and extend the notion that CTRC is a key regulator of diges-
tive zymogen activation.
Chymotrypsin C (CTRC)3 is a digestive protease synthe-
sized and secreted by pancreatic acinar cells as an inactive
precursor (chymotrypsinogen C), which becomes activated in
the duodenum after trypsin cleaves the Arg29–Val30 peptide
bond at the C-terminal end of the propeptide. The severed
propeptide remains attached to CTRC through a disulfide
bond. CTRC exhibits chymotrypsin-like substrate specificity
as it cleaves after Phe, Tyr, Leu, Met, Gln, and Asn amino acid
residues (1–3), but CTRC shares higher sequence identity
with pancreatic elastases than with chymotrypsins. CTRC is
best distinguished from chymotrypsins A and B by its signifi-
cantly higher activity on leucyl and glutaminyl peptide bonds
(1–4). In the pancreatic juice of ruminants chymotrypsinogen
C is found in ternary complex with procarboxypeptidase A
(proCPA) and proproteinase E or in binary complex with
proCPA (5–7).
Recently, we identified human CTRC as a specific regulator
of activation and degradation of human cationic trypsinogen
and trypsin (8, 9). Thus, CTRC stimulates autoactivation of
cationic trypsinogen by processing the trypsinogen activation
peptide to a shorter form that is more susceptible to tryptic
activation. Mutation A16V, which changes the first amino
acid in the trypsinogen activation peptide, accelerates CTRC-
mediated processing, and carriers of this mutation are at risk
of developing chronic pancreatitis (8). CTRC can also cleave
the Leu81–Glu82 peptide bond within the calcium binding
loop of cationic trypsin, when calcium concentrations are low,
and the binding loop is unoccupied. The combination of this
cleavage and an autolytic cleavage at Arg122 results in the deg-
radation and complete inactivation of cationic trypsin (9).
CTRC-mediated trypsin degradation is inhibited by calcium,
which at millimolar concentrations stabilizes the calcium
binding loop. Genetic evidence suggests that trypsin degrada-
tion is an important protective mechanism in the pancreas, as
loss-of-function variants of CTRC increase the risk for
chronic pancreatitis (10, 11), and the trypsinogen mutation
R122H, which blocks CTRC-facilitated trypsin degradation by
eliminating the Arg122 autolysis site, causes hereditary pan-
creatitis (9, 12).
Compelled by these observations, we have initiated a sys-
tematic investigation into novel regulatory roles of CTRC in
digestive enzyme activation and degradation. Here, we pres-
ent studies on the function of CTRC in promoting activation
of human proCPA1 and proCPA2. Pancreatic procarboxypep-
tidases are the precursors to digestive exopeptidases responsi-
ble for removal of C-terminal residues from their dietary pro-
tein and peptide substrates (13, 14). A-type carboxypeptidases
(encoded by the CPA1 and CPA2 genes in humans) act on
aromatic and aliphatic amino acid residues exposed by the
action of chymotrypsins and elastases, whereas the B-type
carboxypeptidase (encoded by the CPB1 gene) hydrolyzes
C-terminal Lys and Arg residues generated by tryptic cleav-
ages. Procarboxypeptidases contain a 94–96-amino acid-long
N-terminal propeptide, which acts as a strong inhibitor of the
enzymes, thereby maintaining their zymogen state. The
propeptide consists of an inhibitory globular domain linked
through an -helical connecting segment (helix 3) to the
enzyme core (Fig. 1). Seminal studies on the activation mech-
anism of bovine, porcine, rat, and human procarboxypepti-
dases elucidated that activation is initiated by tryptic cleavage
at the C terminus of the connecting segment, which destabi-
lizes helix 3 and leads to the dissociation of the inhibitory
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domain (13–23). In the case of proCPA2 and proCPB, trypsin
produced a monophasic activation curve, suggesting that
trypsin alone was sufficient to cause propeptide dissociation
and complete enzyme activation. In contrast, tryptic activa-
tion of proCPA1 was found biphasic, indicating that multiple
proteolytic cleavages of the propeptide were necessary for
the development of full CPA1 activity (13, 21). In porcine
proCPA1, these cleavages occurred at a slow rate, and some
were assumed to result from atypical trypsin activity at non-
canonical sites (19). In addition to the critical role of trypsin,
chymotrypsin and elastase were also shown in several studies
to catalyze procarboxypeptidase activation to varying degrees;
however, neither the mechanism nor cleavage sites involved
in these alternative activation pathways have been clarified
(16, 17, 22, 24). To date, no convincing attempt has been
made to reconcile all biochemical data and define the likely
physiological mechanism of procarboxypeptidase activation
in the gut. Here, we describe that CTRC is a potent co-activa-
tor of human proCPA1 and proCPA2, as it facilitates dissocia-
tion of the propeptide and thereby increases carboxypeptidase
activity by almost an order of magnitude. CTRC exerts its
effect by proteolyzing the -helical connecting segment of the
propeptide, which becomes accessible only after tryptic acti-
vation. Because other human pancreatic proteases are much
less effective at promoting procarboxypeptidase activation,
CTRC emerges as a novel physiological co-activator of human
proCPA1 and proCPA2.
EXPERIMENTAL PROCEDURES
Materials—Cell culture media and a Lipofectamine 2000
transfection reagent were obtained from Invitrogen. Car-
boxypeptidase substrates N-[4-methoxyphenylazoformyl]-L-
phenylalanine and N-[4-methoxyphenylazoformyl)-L-arginine
were purchased from Bachem (Torrance, CA). Human cati-
onic trypsinogen (PRSS1) and proelastase 2A (ELA2A) were
expressed in Escherichia coli and purified by ecotin affinity
chromatography as described (25–28). Trypsinogen was acti-
vated to trypsin with human enteropeptidase (R&D Systems,
Minneapolis, MN). Human CTRC, chymotrypsinogen B1
(CTRB1), chymotrypsinogen B2 (CTRB2), chymotrypsin-like
enzyme-1 precursor (CTRL1), proelastase 3A (ELA3A), and
proelastase 3B (ELA3B) were expressed in HEK 293T cells
and purified from the conditioned medium by ecotin affinity
chromatography (9, 28). CTRC, CTRL1, and ELA3B were pu-
rified as zymogens, whereas CTRB1, CTRB2, and ELA3A
were purified after activation with trypsin. Human SPINK1
(serine protease inhibitor Kazal type 1) was expressed in HEK
293T cells and purified on a bovine trypsin affinity column
(29). Chymotrypsinogens and proelastases were activated
with immobilized bovine trypsin (Pierce; Thermo Fisher Sci-
entific), and the trypsin-containing beads were removed by
centrifugation. Protease concentrations were determined by
active site titration with ecotin. Ecotin was expressed in E. coli
and purified as described previously (30, 31).
Nomenclature—Amino acid residues were numbered start-
ing with the initiator methionine of the primary translation
product; according to the recommendations of the Human
Genome Variation Society. The open reading frame of the
human preproCPA2 contains two methionines at its N termi-
nus (Met-Ala-Met-Arg-). Experimental evidence as to which
methionine is used for translation initiation is lacking. Align-
ment with other mammalian CPA2 preproenzymes indicates
that only the second methionine is conserved. Therefore, we
arbitrarily designated the second methionine as the first
amino acid residue of human preproCPA2.
Plasmid Construction and Mutagenesis—The cDNA for
human preproCPA1 was amplified by PCR from IMAGE
clone 3949850 (GenBankTM accession no. BC005279) using
the CPA1-XhoI sense primer (5-TTT AAA CTC GAG ACC
TTC CCT CCC GGC AGC AGC ATG-3 (where the XhoI
site is underlined)) and the CPA1-BamHI antisense primer
(5-TTT AAA GGA TCC GCA AGC CCC AGG ATT CTG
TTC CTG-3 (where the BamHI site is underlined)). The PCR
product was digested with XhoI and BamHI and subcloned
into the pcDNA3.1() vector. The cDNA for human pre-
proCPA2 was amplified by PCR from IMAGE clone 3950117
(GenBankTM accession no. BC014571) using the CPA2-NheI
sense primer (5-AAA TTT GCT AGC ACT CCA GGA AAA
CCC ATG GCC ATG AGG-3 (where the NheI site is under-
lined)) and the CPA2-EcoRI antisense primer (5-AAA TTT
GAA TTC AAA CCA AAG AGA TTT TAA TGG CTC
FIGURE 1. Ribbon diagram of porcine proCPA1 (Protein Data Bank
code 1PCA) and human proCPA2 (Protein Data Bank code 1AYE).
The propeptides are highlighted in black. The amino acid sequences of
the 3 helices and the flanking tryptic activation sites in human
proCPA1 and proCPA2 are indicated. The side chains for Leu96 (proCPA1
and proCPA2), Arg110 (proCPA1), and Arg112 (proCPA2) are shown. For
clarity, the N-terminal amino acid residues have been removed, and the
structures start with Gln24. The image was rendered using DeepView/
Swiss-PdbViewer (version 3.7).
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TTG-3 (where the EcoRI site is underlined)). The PCR prod-
uct was digested with NheI and EcoRI and subcloned into the
pcDNA3.1() vector. The cDNA for human preproCPB1 was
amplified by PCR from IMAGE clone 4422620 (GenBankTM
accession no. BC015338) using the CPB1-XhoI sense primer
(5-AAA TTT CTC GAG TCA GAC ACA ATG TTG GCA
CTC TTG GTT CTG GTG-3 (where the XhoI site is under-
lined)) and the CPB1-BamHI antisense primer (5-AAA TTT
GGA TCC TCT CAA CTA GTA CAG GTG TTC CAG GAC
GTA-3 (where the BamHI site is underlined)). The PCR
product was digested with XhoI and BamHI and subcloned
into the pcDNA3.1() vector. Construction of pcDNA3.1()
expression plasmids harboring the human CTRC; CTRB1;
and CTRB2, ELA3A, ELA3B, and SPINK1 cDNAs was re-
ported previously (9, 29). The cDNA for human CTRL1 pre-
cursor was PCR-amplified from IMAGE clone 5748224
(GenBankTM accession no. BC039716) with the CTRL1 EcoRI
sense primer (5-AAA TTT GAA TTC TCT GCC ACG ATG
TTG CTG CTC AGC CTG-3 (where the EcoRI site is under-
lined)) and CTRL1 BamHI antisense primer (5-AAA TTT
GGA TCC GTG AGC TCA GTT GTA GGC TAT GAC
CTG-3 (where the BamHI site is underlined)). The PCR
product was digested with EcoRI and BamHI and subcloned
into the pcDNA3.1() vector. The pTrapT7 bacterial expres-
sion plasmids harboring the human PRSS1 and ELA2A
cDNAs were described earlier (25–27). Missense mutations in
proCPA1 and proCPA2 were generated by overlap extension
PCR mutagenesis and cloned in the appropriate expression
plasmids.
Expression and Purification of Human ProCPA1, ProCPA2,
and ProCPB1—HEK 293T cells were grown in DMEM with
10% FBS, and 4 mM L-glutamine in 75 cm2 flasks to 95% con-
fluence. Transfections were carried out using 30 g of plas-
mid DNA and 75 l of Lipofectamine 2000 reagent. After
16–20 h, cells were washed with Opti-MEMmedium and
covered with 20 ml of the same medium. Conditioned media
were harvested after a 48-h incubation; replaced with 20 ml of
fresh Opti-MEM and harvested again at 96 h. Conditioned
media were dialyzed against 20 mM Tris-HCl (pH 8.0) and
loaded directly onto a MonoQ column through the pump of a
Pharmacia FPLC system. The column was developed with a
NaCl gradient (0–0.5 M over 30 min at a flow rate of 1 ml/
min). Fractions (1 ml) were collected and analyzed by SDS-
PAGE and Coomassie Blue staining. The purest fractions
(90%) were used for experiments. Concentrations of the
purified zymogen solutions were estimated from their ultravi-
olet absorbance at 280 nm, using extinction coefficients calcu-
lated with the web-based ProtParam tool.
Measurement of Carboxypeptidase Activity—CPA1 and
CPA2 activity were determined using the N-[4-methoxyphe-
nylazoformyl]-L-phenylalanine substrate at 60 M final con-
centration (32). The assay mix contained 4 l of CPA1/CPA2
enzyme (80 nM, final concentration), 86l of assay buffer (0.1 M
Tris-HCl (pH 8.0) containing 1 mM CaCl2 and 0.05% Tween
20) and 10 l of 0.6 mM substrate dissolved in assay buffer.
CPB1 activity was measured with N-[4-methoxyphenylazo-
formyl)-L-arginine under the same conditions (33). The de-
crease in absorbance was followed at 350 nm for 2 min in a
SPECTRAmax Plus 384 microplate reader (Molecular De-
vices, Sunnyvale, CA). Rates of substrate consumption ob-
tained in mODmin1 units (OD, optical density) were con-
verted to nMs1 values using an extinction coefficient of
19,000 M1 cm1 corrected for the shorter path length of the
microplate wells. Note that addition of ZnCl2 (100 M con-
centration) had no effect on the enzyme activity; therefore, it
was omitted from the routine assay conditions.
Mass Spectrometry—Digestion reactions were stopped by
adding 0.17% TFA (final concentration) and stored frozen.
Prior to mass spectrometry, samples were desalted by micro
solid-phase extraction using C4 ZipTips (Millipore, Billerica,
MA). Briefly, C4 ZipTips were wetted with 80% acetonitrile
and then equilibrated with 2% acetonitrile and 0.1% TFA. Pro-
teins were bound to the resin by pipetting the samples
through the tips several times, and the tips were washed with
2% acetonitrile and 0.1% TFA by pipetting this solution
through the tip twice. Proteins were eluted with 10 l 80%
acetonitrile into Eppendorf tubes and transferred to 96-well
plates (Advion, Ithaca, NY). High resolution mass spectra
were acquired with direct infusion at a flow rate of 10 l/min
on a LTQ-OrbitrapTM hybrid mass spectrometer (Thermo
Fisher Scientific) equipped with a TriVersa NanoMate ion
source (Advion). Electrospray ionization was carried out at
1.7 kV using the NanoMate, with the LTQ heated capillary set
to 150 °C. Mass spectra were acquired in the positive ion
mode over the rangem/z 300–2000 at a resolution of 60,000
(1 mass spectrum/s). Mass accuracy after internal calibra-
tion was within 4 ppm. Data acquisition and analysis were
performed using XCalibur software (Thermo Fisher Scien-
tific). Experimental mass values were assigned to specific pep-
tide sequences by PAWS software (Genomic Solutions, Hol-
liston, MA).
RESULTS
Expression and Purification of Human ProCPA1 and
ProCPA2—Human proCPA1 and proCPA2 were expressed in
transiently transfected HEK 293T cells and purified from the
conditioned medium as described under “Experimental Pro-
cedures.” N-terminal sequencing of the mature zymogens
yielded homogeneous sequences of Lys-Glu-Asp-Phe-Val for
proCPA1 and Leu-Glu-Thr-Phe-Val for proCPA2, which cor-
responded to the N termini expected after removal of the se-
cretory signal peptide (34, 35). Catalytic parameters were de-
termined for the fully activated CPA1/CPA2 enzymes on
the N-[4-methoxyphenylazoformyl]-L-phenylalanine substrate
(supplemental Table S1). The kcat/Km values were comparable
with or higher than those reported in the literature for native
or recombinant human CPA1/CPA2 using small substrates
(36–38).
Activation of Human ProCPA1 and ProCPA2 with Trypsin—
Procarboxypeptidases (2 M concentration) were incubated
with human cationic trypsin (100 nM concentration), and the
digestion products were visualized by SDS-PAGE. As shown
in Fig. 2, trypsin converted the zymogen bands to a car-
boxypeptidase band and a smaller band (12 kDa) corre-
sponding to the released N-terminal propeptide. The reaction
was nearly complete within 5 min, and both bands appeared
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stable up to 80 min showing no signs of further degradation.
N-terminal sequencing of the propeptides showed the same N
termini as observed for the intact proenzymes, confirming
that trypsin only cleaved at the C-terminal end of the propep-
tides. N-terminal sequencing of the CPA1 and CPA2 bands
revealed homogeneous sequences of Ala-Arg-Ser-Thr-Asp
and Ser-Gly-Asn-Phe-Asn, respectively, indicating that tryp-
sin digested the Arg110–Ala111 (proCPA1) and Arg112–Ser113
(proCPA2) peptide bonds, known sites of tryptic activation
(19, 23). To confirm the importance of these sites, Arg110 in
proCPA1 and Arg112 in proCPA2 were mutated to Gln. As
expected, these mutations dramatically reduced the rate of
activation of both proenzymes by trypsin (Fig. 2).
Mass spectrometry of the CPA1/CPA2 propeptides, on the
other hand, showed that the C-terminal amino acid after a
5-min trypsin activation was mainly Arg108, consistent with
tryptic cleavages of the Arg108–Ser109 (proCPA1) and Arg108–
Arg109 (proCPA2) peptide bonds (supplemental Tables S2–
S4). Propeptide forms ending in Arg110 (CPA1, CPA2) and
Arg112 (CPA2) were also detected in lower amounts. Taken
together with the N-terminal sequencing results (see above)
and considering the protective effects of the R110Q
(proCPA1) and R112Q (proCPA2) mutations, these observa-
tions suggest that trypsin acts in a sequential manner. First, it
cleaves proCPA1 after Arg110, followed by cleavage after
Arg108. In proCPA2, trypsin cleaves first after Arg112 and sub-
sequently at Arg110 and Arg108, in agreement with previously
published data (23). Thus, trypsin removes two amino acids
(Ser109–Arg110) from proCPA1 and four amino acids (Arg109–
Arg110-Glu111–Arg112) from proCPA2 and generates stable,
92-amino acid-long propeptides from both human proen-
zymes (Fig. 1). Note that in proCPA2 helix 3 of the connect-
ing segment is longer by a turn than in proCPA1; however,
the 3 helices in the two proenzymes are trimmed to the
same length as a result of tryptic activation.
Activity of Trypsin-activated CPA1 and CPA2 Is Markedly
Increased by CTRC—Activation of proCPA1 or proCPA2 with
human cationic trypsin resulted in the rapid appearance of
carboxypeptidase activity, which reached a plateau at10
min and remained stable afterward (Fig. 3). Addition of rela-
tively low concentrations of CTRC (50 nM) to trypsin-acti-
vated CPA1 or CPA2 caused a sudden and dramatic increase
in carboxypeptidase activity, which was 8–10-fold higher
than the activity obtained after trypsin-mediated activation
alone (Fig. 3). Incubation of proCPA1 or proCPA2 with
CTRC alone yielded no measurable carboxypeptidase activity,
indicating that CTRC-mediated activation was dependent on
prior tryptic activation of the carboxypeptidase zymogens. As
expected, mutation of the catalytic serine 216 to alanine in
CTRC abolished the activating effect of CTRC (data not
shown). The observations suggest that trypsin-mediated acti-
vation of proCPA1 or proCPA2 does not result in complete
dissociation of the inhibitory propeptide and subsequent
cleavage(s) by CTRC are required for the complete elimina-
tion of inhibition and development of full carboxypeptidase
activity. CTRC had no effect on the activity of CPB1 activated
with trypsin (data not shown).
Trypsin-processed Propeptides Are Tight Binding Inhibitors
of CPA1/CPA2—The partial (10%) activity of trypsin-acti-
vated proCPA1/proCPA2 suggests that the trypsin-severed
propeptide is still bound to the enzyme; however, either its
binding affinity is weakened resulting in partial dissociation,
or the propeptide underwent a conformational change par-
tially exposing the active site. To distinguish between these
two scenarios, we measured the concentration dependence of
enzyme activity of trypsin-activated proCPA1/proCPA2. If
the 10% activity is due to a conformational change of the
bound propeptide, the concentration-activity relationship
should be linear. On the other hand, if the 10% activity is due
to weakened binding and partial dissociation of the propep-
tide, the concentration-activity relationship would show a
square-root function; in agreement with the law of mass ac-
tion. The experimental data shown in Fig. 4 clearly supported
the latter case. In contrast, the concentration-activity rela-
tionships for CPA1/CPA2 fully activated with trypsin and
CTRC gave completely linear functions (supplemental Fig.
S1). The equilibrium dissociation constants (KD) for the bind-
FIGURE 2. Activation of proCPA1 (A), proCPA2 (B), the R110Q proCPA1
mutant (A), and the R112Q proCPA2mutant (B) by trypsin. Carboxypep-
tidase zymogens were incubated at 2 M concentration with 100 nM human
cationic trypsin at 37 °C in 20 mM Tris-HCl (pH 8.0) and 50 mM NaCl (final
concentrations) in 100 l final volume. At the indicated times, samples were
precipitated with 10% trichloroacetic acid (final concentration) and ana-
lyzed by 15% SDS-PAGE and Coomassie blue staining. PageRuler prestained
protein ladder was used to provide molecular mass markers (Fermentas,
Glen Burnie, Maryland).
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ing of the CPA1/CPA2 propeptides were estimated from Fig.
4 as 0.8 nM.
CTRCDegrades Trypsin-processed CPA1/CPA2 Propeptides—
CTRC alone did not cleave the intact proCPA1 and proCPA2
zymogens to any detectable extent, as judged by SDS-PAGE
(data not shown). In contrast, addition of CTRC to trypsin-
activated CPA1/CPA2 resulted in relatively rapid degradation
of the propeptide (Fig. 5). Catalytically impaired carboxypep-
tidase variants were also produced by mutating Arg237 in
CPA1 and Arg235 in CPA2 to Ala. Arg237 corresponds to
Arg127 in the mature CPA1 enzyme; and mutation of this
amino acid in rat CPA1 was previously shown to decrease
catalytic activity by four orders of magnitude (39, 40). The
trypsin-processed propeptides of the R237A proCPA1 and
R235A proCPA2 mutants were also readily degraded by
CTRC (Fig. 4), indicating that CPA1/CPA2 activity is not re-
quired for propeptide degradation.
To determine CTRC cleavage sites in the propeptides, the
digestion product mixtures were analyzed by mass spectrom-
etry. These efforts were hampered by the fact that CPA1/
CPA2 removed C-terminal amino acids exposed by CTRC-
mediated cleavages. Therefore, we first analyzed the
catalytically impaired proCPA1 R237A and proCPA2 R235A
mutants (supplemental Table S2). Second, Leu96–Leu97 were
replaced with Ile in this inactive background, and the result-
ing mutants L96I,L97I,R237A (proCPA1) and
L96I,L97I,R235A (proCPA2) were tested (supplemental Table
S3). Because CTRC cannot cleave after Ile, these mutants
were expected to allow us to capture early cleavage intermedi-
FIGURE 3. Activation of proCPA1 (A) and proCPA2 (B) by trypsin and
CTRC. Carboxypeptidase zymogens were incubated at 2 M concentration
with 100 nM human cationic trypsin (open circles), 50 nM CTRC (solid trian-
gles) or 50 nM CTRC added after 15 min preincubation with 100 nM trypsin
(solid circles). Incubations were performed at 37 °C in 20 mM Tris-HCl (pH
8.0), 50 mM NaCl, and 0.05% Tween 20 (final concentrations) in 100 l final
volume. At the indicated times, carboxypeptidase activity was measured as
described under “Experimental Procedures.” The 100% activity levels corre-
sponded to 450 nMs1 (CPA1) and 340 nMs1 (CPA2) substrate cleavage
rates.
FIGURE 4. Concentration dependence of carboxypeptidase activity of
proCPA1 (A) and proCPA2 (B) activated with trypsin. Carboxypeptidase
zymogens were incubated at 2 M concentration with 100 nM human cati-
onic trypsin at 37 °C in 0.1 M Tris-HCl (pH 8.0), 50 mM NaCl, 1 mM CaCl2, and
0.05% Tween 20 (final concentrations) in 100 l final volume. After 30 min
of incubation, activated proenzymes were diluted to the indicated concen-
trations with assay buffer (0.1 M Tris-HCl (pH 8.0), 1 mM CaCl2, 0.05% Tween
20) and incubated for 10 min at 22 °C. Carboxypeptidase activity was
thenmeasured by adding 10l ofN-[4-methoxyphenylazoformyl]-L-phenyl-
alanine substrate to 60 M final concentration, as described under “Experi-
mental Procedures.” Carboxypeptidase activities were converted to free
CPA1/CPA2 concentrations by dividing the activity values with the slope of
the linear concentration-activity plots of trypsin and CTRC activated CPA1/
CPA2 shown in supplemental Fig. S1. Data points were fitted to the equa-
tion y (K sqrt(K 2 4Kx))/2, where K is the equilibrium dissociation
constant. This equation is the positive solution to the K y2/x y quadratic
equation, which expresses the law of mass action applied to the dissocia-
tion of carboxypeptidase and its propeptide. The variable x corresponds to
the total concentration of trypsin-activated proCPA1/proCPA2 present
in the reaction, and y is the concentration of free CPA1/CPA2 in equilibrium.
The concentration of the inhibited CPA1/CPA2 complex in equilibrium is
described by x y.
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ates in the C-terminal half of helix 3. Finally, to estimate the
contribution of CPA1/CPA2 activity to propeptide degrada-
tion, the wild-type proenzymes were studied (supplemental
Table S4). Taken together, the results from these three data
sets indicated that CTRC first cleaved within the C-terminal
third of helix 3 (1 min), followed by cleavages at the N-ter-
minal end of the helix (1 min, 10 min). These cleavages desta-
bilized the globular inhibitory domain, which was then
cleaved by CTRC and trypsin at multiple sites (10 min, 30
min). From comparison of the time course of propeptide deg-
radation by CTRC and the development of carboxypeptidase
activity (Fig. 3), it was apparent that degradation of helix 3
was sufficient to induce complete dissociation of the inhibi-
tory propeptide. The location of the specific CTRC cleavage
sites were determined as described in the following section.
After tryptic activation, CTRC first attacked peptide bonds
located in the C-terminal third of helix 3 in both proCPA1
and proCPA2. CTRC cleaved the Phe105–Ala106 and Gln103–
Met104 peptide bonds in proCPA1; and the Phe106–Asn107
and Met104–Leu105 peptide bonds in proCPA2, most likely in
a sequential manner. The Met104–Phe105 peptide bond in
proCPA1 and the Leu105–Phe106 peptide bond in proCPA2
were also cleaved at low but detectable levels. CPA1/CPA2
activity probably also contributed to the digestion of the
propeptides by removing the C-terminal residues exposed by
CTRC, although the exact cleavages could not be ascertained
from the results.
The N-terminal end of helix 3 was cleaved first at the con-
served Leu96–Leu97 peptide bond in both proCPA1 and
proCPA2. This was followed by cleavage of the Gln94–Ser95
peptide bond in proCPA1. Digestion of the analogous Gln94–
Val95 peptide bond in proCPA2 was less significant. In
proCPA1, Leu96 was removed by CPA1 after CTRC cleavage
of the Leu96–Leu97 peptide bond and Gln94 and Val93 were
sequentially excised after CTRC cleavage of the Gln94–Ser95
peptide bond. In proCPA2, Leu96 and Val95 were removed by
CPA2 after CTRC cleavage of the Leu96–Leu97 peptide bond.
At longer digestion times (10–30 min), several smaller pep-
tides were detected, which were generated by a combination
of chymotryptic and tryptic cleavages within the inhibitory
domain of the propeptide. Thus, in proCPA1 cleavages were
detected at the Leu26–Arg27, Arg27–Ile28, Gln37–Lys38,
Leu48–Gln49, Leu50–Asp51, Arg54–Gly55, Gln73–Ala74, Lys76–
Ile77, and Phe78–Leu79 peptide bonds, whereas in proCPA2,
peptide bonds Leu26–Glu27, Lys37–Asn38, Leu39–Leu40,
Leu40–Gln41, Leu48–Gln49, Leu50–Asp51, Lys54–Ser55, Phe69–
Val70, Lys76–Val77, and Phe78–Leu79 were cleaved (supple-
mental Table S2).
Cleavage of Conserved Leu96–Leu97 Peptide Bond Is Re-
quired for Full CPA1/CPA2 Activation—To test whether
complete degradation of helix 3 is necessary for the develop-
ment of full CPA1/CPA2 activity, amino acids Leu96–Leu97
were mutated to Ile (mutant L96I,L97I) in proCPA1 and
proCPA2. In these mutants, CTRC is expected to cleave at the
C-terminal half of helix 3; however, cleavage at the N termi-
nus of helix 3 would be inhibited, as CTRC cannot digest
isoleucyl peptide bonds. Addition of CTRC to the trypsin-
activated L96I,L97I proCPA1 mutant resulted in a biphasic
activation pattern. First, carboxypeptidase activity rapidly
increased to30% of the potential maximum, followed by a
slow increase to50% during the time course studied (Fig. 6).
In the case of the L96I, L97I proCPA2 mutant a similar bipha-
sic pattern was evident; the rapid phase resulted in about 15%
activity, which slowly increased to35%. These observations
clearly indicate that cleavage in the C-terminal part of helix
3 of the propeptide results in partial CPA1/CPA2 activation
only and cleavage of the conserved Leu96–Leu97 peptide bond
at the N terminus of helix 3 is required for full activation.
CTRC Is Physiological Co-activator of ProCPA1 and
ProCPA2—The robust procarboxypeptidase activating action
of CTRC was unique among human pancreatic proteases,
suggesting that CTRC is the physiological co-activator of
proCPA1 and proCPA2. Thus, incubation with 50 nM concen-
FIGURE 5. Activation of proCPA1 (A), proCPA2 (B), the R237A proCPA1
mutant (A), and the R235A proCPA2mutant (B) by trypsin (Tr) and
CTRC. Procarboxypeptidases were incubated at 2 M concentration with
100 nM human cationic trypsin at 37 °C in 20 mM Tris-HCl (pH 8.0), 50 mM
NaCl (final concentrations) in 100 l final volume. After 5 min, 50 nM CTRC
(final concentration) was added to the incubation reactions. At the indi-
cated times, samples were precipitated with 10% trichloroacetic acid (final
concentration) and analyzed by 15% SDS-PAGE and Coomassie Blue stain-
ing. PageRuler prestained protein ladder was used to provide molecular
mass markers (Fermentas).
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tration of elastase 2A (ELA2A), elastase 3A (ELA3A), elastase
3B (ELA3B), chymotrypsin B1 (CTRB1); chymotrypsin B2
(CTRB2) or chymotrypsin-like enzyme-1 (CTRL1) resulted in
minimal or limited further activation of trypsin-activated
CPA1 and CPA2 (Fig. 7). Interestingly, chymotrypsin B2
(CTRB2) activated the trypsin-processed CPA1 relatively rap-
idly, but the maximal carboxypeptidase activity was only
30% of that achieved by CTRC. Mass spectrometry indi-
cated that CTRB2 cleaved the trypsin-processed CPA1
propeptide at the Phe105–Ala106 peptide bond (data not
shown). These observations also provided independent con-
firmation that proteolytic cleavage in the C-terminal third of
helix 3 can induce only partial CPA1 activation, as described
in the previous section.
Trypsin-independent Activation of ProCPA1 by CTRB2—
We found that CTRB2 at 100–200 nM concentration could
slowly cleave the intact proCPA1 propeptide and thereby
elicit partial CPA1 activation (30% of potential maximum),
even without prior activation with trypsin (Fig. 8). However,
relative to the trypsin-mediated propeptide cleavage, this re-
action proceeded at least 10-fold slower suggesting that it is
unlikely to be of physiological significance. Addition of CTRC
to the CTRB2-activated CPA1 resulted in full CPA1 activity
(Fig. 8). CTRB2 cleaved the Phe105–Ala106 and Phe107–Arg108
peptide bonds in the C-terminal half of helix 3, in an un-
specified order, as evidenced by mass spectrometry (C-termi-
nal residue of cleaved propeptide was Phe105; data not shown)
and N-terminal sequencing (N terminus of CPA1 was Arg108).
DISCUSSION
The present study offers compelling evidence that the hu-
man A-type procarboxypeptidases are activated by the se-
quential action of trypsin and CTRC. The activation mecha-
nism of proCPA1 and proCPA2 can be arbitrarily divided into
four phases. (i) A series of trypsin-mediated cleavages at the C
terminus of the propeptide, which result in the removal of
two amino acid residues (Ser109–Arg110 in proCPA1) or four
amino acid residues (Arg109–Arg110–Glu111–Arg112 in
proCPA2) and generate a stable 92-amino acid-long propep-
tide. This propeptide is still inhibitory; however, binding is
already compromised as evidenced by the appearance of
10% carboxypeptidase activity. (ii) The propeptide is
cleaved by CTRC in the C-terminal third of helix 3 at multi-
ple adjacent sites. Amino acids exposed by CTRC cleavages
may be trimmed by CPA1/CPA2 action. The inhibitory po-
tential of the propeptide is further reduced by these cleavages,
FIGURE 6. Activation of the L96I,L97I proCPA1 (A) and L96I,L97I
proCPA2 (B) mutants by trypsin and CTRC. Procarboxypeptidase mu-
tants and wild-type control were incubated at 2 M concentration with
100 nM human cationic trypsin for 15 min followed by 50 nM CTRC (final
concentrations). Incubations were performed at 37 °C in 20 mM Tris-HCl
(pH 8.0), 50 mM NaCl and 0.05% Tween 20 (final concentrations) in 100
l final volume. At the indicated times, carboxypeptidase activity was
measured as described under “Experimental Procedures.” The 100% ac-
tivity levels corresponded to 450 nMs1 (CPA1) and 340 nMs1 (CPA2)
substrate cleavage rates.
FIGURE 7. Activation of proCPA1 (A) and proCPA2 (B) by trypsin and
human pancreatic proteases. Carboxypeptidase zymogens were incu-
bated at 2 M concentration with 100 nM human cationic trypsin for 15 min
followed by 50 nM of the indicated proteases (final concentrations). Incuba-
tions were performed at 37 °C in 20 mM Tris-HCl (pH 8.0), 50 mM NaCl, and
0.05% Tween 20 (final concentrations) in 100 l final volume. At given
times, carboxypeptidase activity was measured as described under “Experi-
mental Procedures.” The 100% activity levels corresponded to 450 nMs1
(CPA1) and 340 nMs1 (CPA2) substrate cleavage rates.
CTRC Activates Procarboxypeptidases A1 and A2
JANUARY 21, 2011•VOLUME 286•NUMBER 3 JOURNAL OF BIOLOGICAL CHEMISTRY 1825
 at Boston University M
edical Library, on January 14, 2011
w
w
w
.jbc.org
D
ow
nloaded from
 
which results in the development of30% (CPA1) and 15%
(CPA2) of the potential maximal carboxypeptidase activity.
(iii) Helix 3 is cleaved by CTRC at its N terminus at the con-
served Leu96–Leu97 peptide bond. Leu96 is removed by CPA1/
CPA2 activity, and the CPA2 propeptide is further shortened
by excision of Val95, whereas in proCPA1, Ser95 is digested
inefficiently. Instead, CTRC cleaves the Gln94–Ser95 peptide
bond in proCPA1. At this stage, helix 3 of the propeptide is
fully degraded, and CPA1/CPA2 are relieved of inhibition,
resulting in full carboxypeptidase activity. (iv) CTRC and
trypsin digest the dissociated globular domain of the propep-
tide to small peptides. In the physiological setting, other pro-
teases are likely to contribute to this last phase.
The activation mechanism described above conforms to the
general principles of the previously proposed activation path-
ways (13, 19–21). Thus, trypsin cleavage at the C-terminal
end of the propeptide is an obligatory initiating event in
proCPA1/proCPA2 activation, which destabilizes helix 3
and renders it susceptible to further proteolytic attack. Previ-
ous studies on porcine CPA suggested that these were cata-
lyzed by slow and sometimes atypical tryptic cleavages (19);
however, here, we clearly show that the trypsin-cleaved
propeptide is highly stable and efficient proteolysis of helix 3
can be catalyzed by CTRC only. Although CPA1 and CPA2
contribute to the degradation of their own propeptides, this
activity does not seem essential as the propeptides of catalyti-
cally impaired CPA1/CPA2 mutants are also completely de-
graded by trypsin and CTRC (see Fig. 5). In contrast to pub-
lished reports suggesting that proCPA2 is activated by trypsin
alone (13, 18, 21–23), we found that the activation mecha-
nism of proCPA1 and proCPA2 are highly similar and de-
pendent on both trypsin and CTRC. On the other hand, acti-
vation of proCPB1 does not require CTRC and most likely
depends on trypsin only, as described previously (13, 18, 20–
21, 41).
Alignment of rat, mouse, bovine, porcine, and human
CPA1/CPA2 propeptides indicates that Leu96–Leu97 is com-
pletely conserved and CTRC-sensitive sites in the C-terminal
half of helix 3 are also present in these species. Therefore, it
is likely that the activation mechanism identified in this study
is generally applicable to all mammalian procarboxypepti-
dases of the A-type. It is intriguing to note that CTRC is
found in complex with CPA and proproteinase E (which cor-
responds to ELA3B in humans) in ruminants, including the
cow, goat, and sheep (5–7). It would seem reasonable to spec-
ulate that in these species CPA activation is further enhanced
by steric proximity of CPA and its co-activator CTRC. Sur-
prisingly, however, it has been reported that CPA is activated
by trypsin very slowly in the bovine ternary complex, even
though CTRC activation was relatively rapid, indicating that
the CPA propeptide is poorly accessible to CTRC in the com-
plex (15).
Previous studies suggested that chymotrypsin and elastase
might activate procarboxypeptidases in the absence of trypsin
(16, 17, 22, 24). We found, however, that human elastases and
chymotrypsins, other than CTRC, activated proCPA1/
proCPA2 poorly, even after activation with trypsin (see Fig.
7). The only exception was CTRB2, which cleaved the intact
CPA1 propeptide and induced partial (30%) activation of
proCPA1 but at a rate that was by an order of magnitude
slower than trypsin-catalyzed proCPA1 activation. Therefore,
CTRB2 is unlikely to play a significant role in physiological
proCPA1/proCPA2 activation.
Finally, the results presented here confirm and extend the
notion that CTRC is a unique digestive protease which, be-
yond its digestive function, also plays an important role in
regulating the activation and degradation of other digestive
enzymes, trypsinogens (8, 9), and procarboxypeptidases in
particular. Other human pancreatic chymotrypsins and elas-
tases are ineffective at cleaving the CTRC-specific regulatory
sites. The specificity of CTRC can be partly explained by its
affinity for leucyl peptide bonds. Furthermore, alignment of
sequences flanking the regulatory cleavage sites in trypsino-
gen and the Leu96–Leu97 peptide bond in proCPA1/proCPA2
reveals a clustering of acidic amino acid residues on the prime
FIGURE 8. Activation of proCPA1 by CTRB2. A, procarboxypeptidase A1
was incubated at 2 M concentration with 100 nM (solid symbols) or 200 nM
(open symbols) CTRB2 for 60 min followed by 50 nM CTRC (final concentra-
tions). Incubations were performed at 37 °C in 20 mM Tris-HCl (pH 8.0), 50
mM NaCl, and 0.05% Tween 20 (final concentrations) in 100 l final volume.
Reactions also contained human SPINK1 at 70 nM concentration to inhibit
any unforeseen trypsin contamination. At given times, carboxypeptidase
activity was measured as described under “Experimental Procedures.” The
100% activity level corresponded to 450 nMs1 substrate cleavage rate.
B, alternatively, reactions were precipitated with 10% trichloroacetic acid
(final concentration) and analyzed by 15% SDS-PAGE and Coomassie Blue
staining. The experiment shown was performed with 100 nM CTRB2 concen-
tration. Note that CTRB2 is physiologically autolyzed at the Tyr164–Asn165
peptide bond generating 14-kDa and 10.4-kDa fragments on reducing gels.
The larger fragment is clearly visible on the gel, whereas the smaller frag-
ment can be observed as a faint band above the CPA1 propeptide. A
PageRuler prestained protein ladder was used to provide molecular mass
markers (Fermentas).
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side of the scissile peptide bonds (supplemental Table S5). It
appears likely that (some of) these acidic residues might gov-
ern CTRC recognition and impart high specificity to CTRC-
mediated cleavages.
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